Ipilimumab Market Comprehensive Insight by Growth Rate, Industry Status, Forecast till 2028

 

The global ipilimumab market is anticipated to grow at a CAGR of 8.5% during the forecast period (2022-2028). The rising prevalence of melanoma is driving the demand for ipilimumab. According to the American Cancer Society (ACS), about 99,780 new melanomas is expected to be diagnosed (about 57,180 in men and 42,600 in women). Due to the patent expiration of key branded biologics, the number of biosimilars entering the market which is expected to offer an opportunity for the market growth during the forecast period. For instance, Amgen’s patent for Imlygic is set to expire in 2021, which is expected to open the door for new players to enter the market and boost the market growth.

Some of the key players profiled in the study are: Gilead Sciences Inc., Bristol-Myers Squibb Co., and F. Hoffmann-La Roche Ltd., among others.

Ipilimumab Market Segmentation:

By Type 

• L1 Antagonists
• CTLA4 Antagonists
• Immune checkpoint Inhibitors
• Others

By Application 

• Cancer
• Melanoma
• Others

Geographic Coverage

• North America Market Size and/or Volume
• Latin America Market Size and/or Volume
• Europe Market Size and/or Volume
• Asia-Pacific Market Size and/or Volume
• Rest of the world Market Size and/or Volume

Key questions answered in this report:

• What is the size of the Ipilimumab market and what is its expected growth rate?
• What are the primary driving factors that push the Ipilimumab Market forward?
• What are the Ipilimumab Industry’s top companies?
• What are the different categories that the Ipilimumab Market caters to?
• What will be the fastest-growing segment or region?
• In the value chain, what role do essential players play?
• What is the procedure for getting a free copy of the Ipilimumab Market sample report and company profiles?